title: Yttrium-90 radioembolization using TheraSphere in the management of primary and secondary liver tumors.
abstract: Locoregional therapies, such as transarterial chemoembolization, radioembolization and thermal ablation (e.g., radiofrequency ablation) are establishing their roles in the management of liver malignancies. With yYttrium-90 radioembolization therapy (90Y) radionuclide labeled microspheres are injected into the tumor feeding artery. This allows the delivery of a high radioactive dose to the tumor with minimal toxicity to normal tissues. 90Y has demonstrated to be safe and effective in the management of liver tumors. Authors present a review of the literature available for the use of TheraSphere for radioembolization in the management of liver tumors.
authors.affiliation: Department of Radiology, Northwestern University, Chicago, IL 60611, USA.
authors.forename: A
authors.initials: A
authors.lastname: Riaz
authors.forename: R J
authors.initials: RJ
authors.lastname: Lewandowski
authors.forename: L
authors.initials: L
authors.lastname: Kulik
authors.forename: R
authors.initials: R
authors.lastname: Salem
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy* / Q000556:secondary*; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000008:administration & dosage*; D019275:Radiopharmaceuticals / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D015021:Yttrium Radioisotopes / Q000008:administration & dosage*
chemical_list: D011868:Radioisotopes; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes